Is Regression after Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Different in Sentinel and Non-sentinel Nodes?

Gábor Cserni, Tamás Zombori, Xavier Andreu, Simonetta Bianchi, Peter Regitnig, Isabel Amendoeira, Davide Balmativola, Anikó Kovács, Alicia Cordoba, Angelika Reiner, Janina Kulka, Handan Kaya, Inta Liepniece-Karele, Cecily Quinn, Bence Kővári

Research output: Contribution to journalArticle

Abstract

Tumor draining sentinel lymph nodes (SLNs) are the sites of selective changes as compared to non-SLNs. They show features of tumor-reactive lymphadenopathy, including increased total number of functional blood vessels, but a relative immunosuppressed status has also been described in them. We explored the hypothesis of a selective regression or non-regression in SLNs versus non-SLNs in 142 patients with 110 estrogen receptor-positive and 32 estrogen receptor-negative tumors undergoing both SLN biopsy and axillary lymph node dissection after neoadjuvant therapy by assessing the tumoral (metastatic) and regression statuses of SLNs and non-SLNs separately. Of the 89 cases with signs of nodal regression, 22 cases (25%) were in favor of a selective non-regression in SLNs, 18 cases (20%) were supportive of a selective and more pronounced regression in the SLNs and the remaining showed equal degrees of regression or non-regression in SLNs and non-SLNs. The results indicate that there is no obvious difference in the degree of regressive histological changes shown by SLNs and NSLNs. Therefore, this phenomenon may not be a major contributor to the higher false negative rate of SLN biopsy after neoadjuvant treatment.

Original languageEnglish
Pages (from-to)167-170
Number of pages4
JournalPathology and Oncology Research
Volume24
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Breast Neoplasms
Drug Therapy
Lymph Nodes
Sentinel Lymph Node Biopsy
Neoadjuvant Therapy
Estrogen Receptors
Neoplasms
Sentinel Lymph Node
cyhalothrin
Lymph Node Excision
Blood Vessels

Keywords

  • Breast cancer
  • Neoadjuvant therapy
  • Non-sentinel lymph node
  • Selective regression
  • Sentinel lymph node

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

Is Regression after Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Different in Sentinel and Non-sentinel Nodes? / Cserni, Gábor; Zombori, Tamás; Andreu, Xavier; Bianchi, Simonetta; Regitnig, Peter; Amendoeira, Isabel; Balmativola, Davide; Kovács, Anikó; Cordoba, Alicia; Reiner, Angelika; Kulka, Janina; Kaya, Handan; Liepniece-Karele, Inta; Quinn, Cecily; Kővári, Bence.

In: Pathology and Oncology Research, Vol. 24, No. 1, 01.01.2018, p. 167-170.

Research output: Contribution to journalArticle

Cserni, G, Zombori, T, Andreu, X, Bianchi, S, Regitnig, P, Amendoeira, I, Balmativola, D, Kovács, A, Cordoba, A, Reiner, A, Kulka, J, Kaya, H, Liepniece-Karele, I, Quinn, C & Kővári, B 2018, 'Is Regression after Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Different in Sentinel and Non-sentinel Nodes?', Pathology and Oncology Research, vol. 24, no. 1, pp. 167-170. https://doi.org/10.1007/s12253-017-0229-z
Cserni, Gábor ; Zombori, Tamás ; Andreu, Xavier ; Bianchi, Simonetta ; Regitnig, Peter ; Amendoeira, Isabel ; Balmativola, Davide ; Kovács, Anikó ; Cordoba, Alicia ; Reiner, Angelika ; Kulka, Janina ; Kaya, Handan ; Liepniece-Karele, Inta ; Quinn, Cecily ; Kővári, Bence. / Is Regression after Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Different in Sentinel and Non-sentinel Nodes?. In: Pathology and Oncology Research. 2018 ; Vol. 24, No. 1. pp. 167-170.
@article{788baff6b4e24bcfb25b4f3fc72c4b26,
title = "Is Regression after Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Different in Sentinel and Non-sentinel Nodes?",
abstract = "Tumor draining sentinel lymph nodes (SLNs) are the sites of selective changes as compared to non-SLNs. They show features of tumor-reactive lymphadenopathy, including increased total number of functional blood vessels, but a relative immunosuppressed status has also been described in them. We explored the hypothesis of a selective regression or non-regression in SLNs versus non-SLNs in 142 patients with 110 estrogen receptor-positive and 32 estrogen receptor-negative tumors undergoing both SLN biopsy and axillary lymph node dissection after neoadjuvant therapy by assessing the tumoral (metastatic) and regression statuses of SLNs and non-SLNs separately. Of the 89 cases with signs of nodal regression, 22 cases (25{\%}) were in favor of a selective non-regression in SLNs, 18 cases (20{\%}) were supportive of a selective and more pronounced regression in the SLNs and the remaining showed equal degrees of regression or non-regression in SLNs and non-SLNs. The results indicate that there is no obvious difference in the degree of regressive histological changes shown by SLNs and NSLNs. Therefore, this phenomenon may not be a major contributor to the higher false negative rate of SLN biopsy after neoadjuvant treatment.",
keywords = "Breast cancer, Neoadjuvant therapy, Non-sentinel lymph node, Selective regression, Sentinel lymph node",
author = "G{\'a}bor Cserni and Tam{\'a}s Zombori and Xavier Andreu and Simonetta Bianchi and Peter Regitnig and Isabel Amendoeira and Davide Balmativola and Anik{\'o} Kov{\'a}cs and Alicia Cordoba and Angelika Reiner and Janina Kulka and Handan Kaya and Inta Liepniece-Karele and Cecily Quinn and Bence Kőv{\'a}ri",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s12253-017-0229-z",
language = "English",
volume = "24",
pages = "167--170",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Is Regression after Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Different in Sentinel and Non-sentinel Nodes?

AU - Cserni, Gábor

AU - Zombori, Tamás

AU - Andreu, Xavier

AU - Bianchi, Simonetta

AU - Regitnig, Peter

AU - Amendoeira, Isabel

AU - Balmativola, Davide

AU - Kovács, Anikó

AU - Cordoba, Alicia

AU - Reiner, Angelika

AU - Kulka, Janina

AU - Kaya, Handan

AU - Liepniece-Karele, Inta

AU - Quinn, Cecily

AU - Kővári, Bence

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Tumor draining sentinel lymph nodes (SLNs) are the sites of selective changes as compared to non-SLNs. They show features of tumor-reactive lymphadenopathy, including increased total number of functional blood vessels, but a relative immunosuppressed status has also been described in them. We explored the hypothesis of a selective regression or non-regression in SLNs versus non-SLNs in 142 patients with 110 estrogen receptor-positive and 32 estrogen receptor-negative tumors undergoing both SLN biopsy and axillary lymph node dissection after neoadjuvant therapy by assessing the tumoral (metastatic) and regression statuses of SLNs and non-SLNs separately. Of the 89 cases with signs of nodal regression, 22 cases (25%) were in favor of a selective non-regression in SLNs, 18 cases (20%) were supportive of a selective and more pronounced regression in the SLNs and the remaining showed equal degrees of regression or non-regression in SLNs and non-SLNs. The results indicate that there is no obvious difference in the degree of regressive histological changes shown by SLNs and NSLNs. Therefore, this phenomenon may not be a major contributor to the higher false negative rate of SLN biopsy after neoadjuvant treatment.

AB - Tumor draining sentinel lymph nodes (SLNs) are the sites of selective changes as compared to non-SLNs. They show features of tumor-reactive lymphadenopathy, including increased total number of functional blood vessels, but a relative immunosuppressed status has also been described in them. We explored the hypothesis of a selective regression or non-regression in SLNs versus non-SLNs in 142 patients with 110 estrogen receptor-positive and 32 estrogen receptor-negative tumors undergoing both SLN biopsy and axillary lymph node dissection after neoadjuvant therapy by assessing the tumoral (metastatic) and regression statuses of SLNs and non-SLNs separately. Of the 89 cases with signs of nodal regression, 22 cases (25%) were in favor of a selective non-regression in SLNs, 18 cases (20%) were supportive of a selective and more pronounced regression in the SLNs and the remaining showed equal degrees of regression or non-regression in SLNs and non-SLNs. The results indicate that there is no obvious difference in the degree of regressive histological changes shown by SLNs and NSLNs. Therefore, this phenomenon may not be a major contributor to the higher false negative rate of SLN biopsy after neoadjuvant treatment.

KW - Breast cancer

KW - Neoadjuvant therapy

KW - Non-sentinel lymph node

KW - Selective regression

KW - Sentinel lymph node

UR - http://www.scopus.com/inward/record.url?scp=85017188123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017188123&partnerID=8YFLogxK

U2 - 10.1007/s12253-017-0229-z

DO - 10.1007/s12253-017-0229-z

M3 - Article

C2 - 28391512

AN - SCOPUS:85017188123

VL - 24

SP - 167

EP - 170

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 1

ER -